Last reviewed · How we verify

Thromboembolism due to Prosthetic Heart Valves — Treatment Landscape & Competitive Intelligence

Thromboembolism due to Prosthetic Heart Valves (disease) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

1 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Thromboembolism due to Prosthetic Heart Valves, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Coumadin warfarin Generic (originally Wisconsin Alumni Research Foundation) Vitamin K antagonist (anticoagulant) Vitamin K epoxide reductase complex subunit 1-like protein 1, Cytochrome P450 2C9, Proprotein convertase subtilisin/kexin type 7 1954-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Generic (originally Wisconsin Alumni Research Foundation) · 1 drug in Thromboembolism due to Prosthetic Heart Valves

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Thromboembolism due to Prosthetic Heart Valves:

Cite this brief

Drug Landscape (2026). Thromboembolism due to Prosthetic Heart Valves — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/thromboembolism-due-to-prosthetic-heart-valves. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing